Becton, Dickinson and Company (NYSE:BDX) Receives Consensus Rating of “Hold” from Analysts

Shares of Becton, Dickinson and Company (NYSE:BDX) have been assigned an average rating of “Hold” from the seventeen ratings firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, eight have given a hold rating and eight have issued a buy rating on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $187.67.

BDX has been the subject of a number of recent research reports. Evercore set a $180.00 price objective on Becton, Dickinson and Company in a research note on Monday, July 6th. Piper Sandler upped their price target on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Stifel Nicolaus set a $195.00 price objective on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Royal Bank Of Canada lifted their price objective on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a research report on Thursday, August 13th. Finally, UBS Group began coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, July 28th. They set a “buy” rating and a $190.00 target price for the company.

Becton, Dickinson and Company Stock Down 1.7%

Shares of NYSE:BDX opened at $179.45 on Friday. The company’s fifty day moving average is $177.60 and its two-hundred day moving average is $160.93. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $193.07. The stock has a market capitalization of $49.45 billion, a price-to-earnings ratio of 54.05, a price-to-earnings-growth ratio of 12.90 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. The business had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is 126.51%.

Insider Buying and Selling

In related news, CEO Thomas Polen, Jr. sold 4,152 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the sale, the chief executive officer directly owned 110,163 shares in the company, valued at $20,380,155. This trade represents a 3.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the sale, the executive vice president directly owned 19,720 shares in the company, valued at $3,717,022.80. The trade was a 0.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 6,830 shares of company stock valued at $1,251,894 in the last three months. 0.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Becton, Dickinson and Company

Institutional investors have recently bought and sold shares of the stock. Brown Lisle Cummings Inc. grew its holdings in shares of Becton, Dickinson and Company by 9.2% during the second quarter. Brown Lisle Cummings Inc. now owns 644 shares of the medical instruments supplier’s stock valued at $97,000 after buying an additional 54 shares in the last quarter. Elevation Point Wealth Partners LLC lifted its stake in Becton, Dickinson and Company by 3.7% in the 2nd quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier’s stock worth $256,000 after acquiring an additional 60 shares in the last quarter. Private Harbour Investment Management & Counsel LLC lifted its stake in Becton, Dickinson and Company by 1.1% in the 2nd quarter. Private Harbour Investment Management & Counsel LLC now owns 5,511 shares of the medical instruments supplier’s stock worth $834,000 after acquiring an additional 62 shares in the last quarter. NorthRock Partners LLC boosted its position in Becton, Dickinson and Company by 2.0% during the 2nd quarter. NorthRock Partners LLC now owns 3,295 shares of the medical instruments supplier’s stock worth $499,000 after acquiring an additional 65 shares during the period. Finally, QRG Capital Management Inc. grew its stake in Becton, Dickinson and Company by 0.7% during the 2nd quarter. QRG Capital Management Inc. now owns 8,798 shares of the medical instruments supplier’s stock valued at $1,331,000 after acquiring an additional 65 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells products used by healthcare providers, researchers and pharmaceutical companies. Founded in 1897 by Maxwell Becton and Fairleigh Dickinson, the company is headquartered in Franklin Lakes, New Jersey.

BD’s products support medication delivery, infection prevention, diagnostics and surgical care. Its portfolio includes needles, syringes, injection devices, infusion products, medication-management systems, specimen-collection products, laboratory instruments and diagnostic technologies.